Arcutis Biotherapeutics, Inc.
corporate_fare Company Profile
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 15 items for ARQT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 15 most recent items scored 7 or higher, the top rating is 9/10, with 7 rated 8 or above. Recent SEC coverage for ARQT spans 10-Q, 8-K.
Recent high-impact activity:
- Arcutis Sinks ~20% as Q3 Earnings Miss on Surging SG&A, Guidance Still Raised
- Arcutis Lifts Full-Year Sales Guidance to $535M-$545M After 45% Q3 Revenue Jump
- Arcutis 10-Q: Q3 Revenue $143.9M, Nine-Month Profit $12.5M, ATM Upsized to $200M
- Arcutis Q3 Revenue Jumps 45% to $143.9M, Full-Year Guidance Raised to $535-545M
- Arcutis Posts 6-Cent Q3 EPS as Stock Sits Near 52-Week High
Financial Snapshot
Short Interest & Short Volume
7.58 days to coverFINRA reported short interest of 18,157,145 shares in ARQT as of the October 30, 2026 settlement, a 11.4% decrease from the prior period — about 7.6 days to cover at its recent average daily volume. On November 20, 2026, 69.5% of ARQT volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for ARQT, detected from its recent SEC filings · based on capital-structure filings through 2026-11-04.
ATM Prospectus Supplement Filed · No Shares Sold Under Program
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →